Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00899405

Enrollment

800

Registered

2009-05-12

Start date

2004-05-19

Completion date

2034-05-01

Last updated

2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

lung cancer

Brief summary

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

Detailed description

OBJECTIVES: * Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer. * Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients. OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed lung cancer PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * May have received prior EGFR inhibitors

Design outcomes

Primary

Measure	Time frame
Mutational status of the EGFR pathway	up to 1 year

Countries

United States

Contacts

CONTACTOffice of Clinical Research

OCRReferral@health.ucdavis.edu916-382-6970

PRINCIPAL_INVESTIGATORJonathan Riess, MD

University of California, Davis

Outcome results